| Independent and combined effects of improved water, sanitation, and hygiene, and improved complementary feeding, on child stunting and anaemia in rural Zimbabwe: a cluster … JH Humphrey, MNN Mbuya, R Ntozini, LH Moulton, RJ Stoltzfus, ... The Lancet Global Health 7 (1), e132-e147, 2019 | 592 | 2019 |
| Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate XQ Li, A Björkman, TB Andersson, M Ridderström, CM Masimirembwa The Journal of pharmacology and experimental therapeutics 300 (2), 399-407, 2002 | 360 | 2002 |
| Identification of human cytochrome P450s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data XQ Li, A Björkman, TB Andersson, LL Gustafsson, CM Masimirembwa European journal of clinical pharmacology 59 (5), 429-442, 2003 | 302 | 2003 |
| Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges CM Masimirembwa, U Bredberg, TB Andersson Clinical pharmacokinetics 42 (6), 515-528, 2003 | 279 | 2003 |
| A novel mutant variant of the CYP2D6 gene (CYP2D617) common in a black African population: association with diminished debrisoquine hydroxylase activity C MASIMIREMBWA, I PERSSON, L BERTILSSON, J HASLER, ... British journal of clinical pharmacology 42 (6), 713-719, 1996 | 260 | 1996 |
| High prevalence of the CYP2B6 516G→T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe C Nyakutira, D Röshammar, E Chigutsa, P Chonzi, M Ashton, C Nhachi, ... European journal of clinical pharmacology 64 (4), 357-365, 2008 | 250 | 2008 |
| Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz‐Containing Antiretroviral Therapy Z Desta, RS Gammal, L Gong, M Whirl‐Carrillo, AH Gaur, C Sukasem, ... Clinical Pharmacology & Therapeutics 106 (4), 726-733, 2019 | 210 | 2019 |
| The sanitation hygiene infant nutrition efficacy (SHINE) trial: rationale, design, and methods Sanitation Hygiene Infant Nutrition Efficacy (SHINE) Trial Team, ... Clinical Infectious Diseases 61 (suppl_7), S685-S702, 2015 | 177 | 2015 |
| In vitro high throughput screening of compounds for favorable metabolic properties in drug discovery. CM Masimirembwa, R Thompson, TB Andersson Combinatorial chemistry & high throughput screening 4 (3), 245-263, 2001 | 173 | 2001 |
| Competitive CYP2C9 inhibitors: enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis L Afzelius, I Zamora, M Ridderström, TB Andersson, A Karlén, ... Molecular pharmacology 59 (4), 909-919, 2001 | 155 | 2001 |
| African genetic diversity: implications for cytochrome P450-mediated drug metabolism and drug development I Rajman, L Knapp, T Morgan, C Masimirembwa EBioMedicine 17, 67-74, 2017 | 147 | 2017 |
| The potential inhibitory effect of antiparasitic drugs and natural products on P-glycoprotein mediated efflux R Hayeshi, C Masimirembwa, S Mukanganyama, ALB Ungell european journal of pharmaceutical sciences 29 (1), 70-81, 2006 | 142 | 2006 |
| Heterologous expression and kinetic characterization of human cytochromes P-450: validation of a pharmaceutical tool for drug metabolism research CM Masimirembwa, C Otter, M Berg, M Jönsson, B Leidvik, E Jonsson, ... Drug Metabolism and Disposition 27 (10), 1117-1122, 1999 | 141 | 1999 |
| Genetic polymorphism of CYP2D6 and CYP2C19 in east-and southern African populations including psychiatric patients C Dandara, C Mutowembwa Masimirembwa, A Magimba, J Sayi, S Kaaya, ... European journal of clinical pharmacology 57 (1), 11-17, 2001 | 138 | 2001 |
| Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s TE Bapiro, AC Egnell, JA Hasler, CM Masimirembwa Drug metabolism and disposition 29 (1), 30-35, 2001 | 138 | 2001 |
| Phenotyping and genotyping of S‐mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe C Masimirembwa, L Bertilsson, I Johansson, JA Hasler, ... Clinical Pharmacology & Therapeutics 57 (6), 656-661, 1995 | 113 | 1995 |
| Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects A Matimba, J Del-Favero, C Van Broeckhoven, C Masimirembwa Human genomics 3 (2), 169, 2009 | 110 | 2009 |
| CYP2B6 functional variability in drug metabolism and exposure across populations—implication for drug safety, dosing, and individualized therapy IM Langmia, KS Just, S Yamoune, J Brockmöller, C Masimirembwa, ... Frontiers in genetics 12, 692234, 2021 | 102 | 2021 |
| Arginines 97 and 108 in CYP2C9 are important determinants of the catalytic function M Ridderström, C Masimirembwa, S Trump-Kallmeyer, M Ahlefelt, C Otter, ... Biochemical and Biophysical Research Communications 270 (3), 983-987, 2000 | 102 | 2000 |
| CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an … M Dhoro, S Zvada, B Ngara, C Nhachi, G Kadzirange, P Chonzi, ... BMC Pharmacology and Toxicology 16 (1), 4, 2015 | 101 | 2015 |
